aTYR PHARMA Reports Flat Revenue, Widening Net Loss in Q2

TL;DR

**ATYR is burning cash with no revenue, and their recent ATM offering is a drop in the bucket – stay away unless you love high-risk biotech plays.**

AI Summary

aTYR PHARMA INC reported no license and collaboration revenue for the three and six months ended June 30, 2025, consistent with the prior year periods. The company's net loss for the three months ended June 30, 2025, was $14.5 million, a slight increase from the $14.3 million net loss in the same period of 2024. For the six months ended June 30, 2025, the net loss was $29.1 million, compared to $28.5 million in the prior year. Research and development expenses decreased to $10.1 million for the three months ended June 30, 2025, from $10.3 million in 2024, and to $20.3 million for the six months ended June 30, 2025, from $20.7 million in 2024. General and administrative expenses remained relatively stable at $4.4 million for the three months and $8.8 million for the six months ended June 30, 2025. The company's cash, cash equivalents, and investments totaled $60.5 million as of June 30, 2025, down from $75.0 million at December 31, 2024. Subsequent to the quarter, aTYR PHARMA INC sold 1,077,000 shares of common stock through an ATM offering program with Jefferies LLC, generating gross proceeds of approximately $2.1 million between July 1, 2025, and August 6, 2025.

Why It Matters

aTYR PHARMA's continued lack of revenue and persistent net losses of $14.5 million in Q2 2025 signal ongoing challenges for investors, highlighting the long and costly development cycles inherent in the biotech sector. The decline in cash, cash equivalents, and investments from $75.0 million to $60.5 million in six months, coupled with the recent ATM offering raising only $2.1 million, suggests a tightening financial runway. This could impact the company's ability to fund critical clinical trials and compete effectively against larger pharmaceutical companies with deeper pockets, potentially delaying or halting drug development for patients. Employees face uncertainty regarding job security and the long-term viability of their projects if funding becomes constrained, while the broader market watches for signs of successful clinical progression to validate the company's therapeutic approach.

Risk Assessment

Risk Level: high — The company reported no license and collaboration revenue for the three and six months ended June 30, 2025, indicating a lack of commercialized products or significant partnerships. Their cash, cash equivalents, and investments decreased from $75.0 million at December 31, 2024, to $60.5 million at June 30, 2025, representing a 19.3% reduction in liquid assets over six months. This cash burn, combined with a net loss of $14.5 million for Q2 2025, points to significant financial risk.

Analyst Insight

Investors should exercise extreme caution and consider the high burn rate against the limited cash reserves. Monitor upcoming clinical trial results closely, as positive data is crucial for future funding and potential revenue generation. Without a clear path to revenue, the stock remains highly speculative.

Financial Highlights

debt To Equity

N/A

revenue

$0

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

-$14.5 million

eps

N/A

gross Margin

N/A

cash Position

$60.5 million

revenue Growth

0.0%

Revenue Breakdown

Key Numbers

• $0 — License and Collaboration Revenue (for the three and six months ended June 30, 2025, indicating no current revenue streams.)
• $14.5 million — Net Loss (for the three months ended June 30, 2025, an increase from $14.3 million in Q2 2024.)
• $29.1 million — Net Loss (for the six months ended June 30, 2025, compared to $28.5 million in the prior year period.)
• $10.1 million — Research and Development Expenses (for the three months ended June 30, 2025, a slight decrease from $10.3 million in Q2 2024.)
• $60.5 million — Cash, Cash Equivalents, and Investments (as of June 30, 2025, down from $75.0 million at December 31, 2024.)
• $2.1 million — Gross Proceeds from ATM Offering (from July 1, 2025, to August 6, 2025, through Jefferies LLC.)
• 1,077,000 — Shares Sold in ATM Offering (between July 1, 2025, and August 6, 2025.)

Key Players & Entities

• aTYR PHARMA INC (company) — filer of the 10-Q
• Jefferies LLC (company) — underwriter for the ATM offering program
• Jill M. Broadfoot (person) — Chief Financial Officer
• Nancy E. Denyes (person) — Chief Accounting Officer
• 03 Life Sciences (company) — organization name associated with the filer

FAQ

Risk Factors

• Deteriorating Cash Position [high — financial]: The company's cash, cash equivalents, and investments have decreased to $60.5 million as of June 30, 2025, from $75.0 million at December 31, 2024. This represents a significant burn rate and potential need for further financing.
• Increasing Net Loss [medium — financial]: The net loss for the three months ended June 30, 2025, was $14.5 million, a slight increase from $14.3 million in the prior year. The six-month net loss also increased to $29.1 million from $28.5 million, indicating a worsening financial performance.
• Reliance on Equity Financing [medium — financial]: The company recently generated gross proceeds of approximately $2.1 million through an ATM offering program. This highlights a reliance on equity markets for funding, which can be dilutive to existing shareholders.
• No Revenue Generation [high — operational]: The absence of license and collaboration revenue for the reported periods suggests a lack of commercialization success or partnerships, which is a critical concern for a pharmaceutical company.
• Sustained R&D Expenses [medium — operational]: Despite a slight decrease, Research and Development expenses remain substantial at $10.1 million for the quarter and $20.3 million for the six months. Continued high R&D spending without corresponding revenue growth is unsustainable.

Industry Context

The biotechnology and pharmaceutical industry is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies like aTYR PHARMA INC operate in a competitive landscape where success hinges on innovation, clinical trial outcomes, and securing partnerships or funding. The sector is heavily influenced by scientific advancements, patent expirations, and evolving healthcare policies.

Regulatory Implications

As a pharmaceutical company, aTYR PHARMA INC is subject to stringent regulations from bodies like the FDA. Delays in clinical trials, failure to meet efficacy or safety standards, or changes in regulatory pathways can significantly impact development timelines and market access. Compliance with Good Manufacturing Practices (GMP) and other quality standards is also paramount.

What Investors Should Do

1. Monitor cash burn rate and future financing needs.
2. Evaluate the progress of R&D pipeline.
3. Assess the sustainability of operating expenses.

Key Dates

• 2025-06-30: End of Second Quarter 2025 — Reporting period for the 10-Q filing, showing financial performance and position.
• 2025-07-01: Start of ATM Offering Program Activity — Beginning of the period during which the company sold shares, generating $2.1 million in gross proceeds.
• 2025-08-06: End of ATM Offering Program Activity — Conclusion of the period for the reported ATM offering, providing a snapshot of recent capital raising.
• 2025-08-07: 10-Q Filing Date — The date the company officially submitted its quarterly report to the SEC.

Glossary

ATM Offering Program

An 'at-the-market' offering where a company sells shares of its stock over a period of time through one or more stock exchanges at prevailing market prices. (Indicates a method of raising capital by selling existing shares, often used by companies needing ongoing funding.)

License and Collaboration Revenue

Revenue generated from agreements where a company licenses its technology or intellectual property to another entity, or enters into collaborative research and development agreements. (Crucial for pharmaceutical companies to indicate progress in drug development and potential future commercialization.)

Net Loss

The total expenses of a company exceed its total revenues over a specific period, resulting in a negative profit. (A key indicator of a company's profitability, especially important for early-stage or development-focused companies.)

Research and Development Expenses

Costs incurred by a company in the process of developing new products or services, or improving existing ones. (A significant expense for pharmaceutical companies, reflecting investment in future growth and product pipeline.)

Cash, Cash Equivalents, and Investments

Highly liquid financial assets held by a company, including cash on hand, bank deposits, and short-term, highly marketable securities. (Represents the company's immediate liquidity and its ability to fund operations and investments.)

Year-Over-Year Comparison

Compared to the prior year, aTYR PHARMA INC shows a slight increase in net loss for both the three-month ($14.5M vs $14.3M) and six-month ($29.1M vs $28.5M) periods ending June 30, 2025. While R&D expenses saw a minor decrease, the absence of license and collaboration revenue remains a consistent concern. The company's cash position has also significantly declined from $75.0 million at the end of 2024 to $60.5 million by mid-2025, indicating a higher burn rate and increased reliance on recent equity financing.

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share ATYR The Nasdaq Capital M

Filing Documents

• atyr-20250630.htm (10-Q) — 2203KB
• atyr-ex10_2.htm (EX-10.2) — 256KB
• atyr-ex31_1.htm (EX-31.1) — 12KB
• atyr-ex31_2.htm (EX-31.2) — 12KB
• atyr-ex32_1.htm (EX-32.1) — 8KB
• atyr-ex32_2.htm (EX-32.2) — 8KB
• 0001339970-25-000009.txt ( ) — 8844KB
• atyr-20250630.xsd (EX-101.SCH) — 1140KB
• atyr-20250630_htm.xml (XML) — 1541KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements 3 Condensed Consolidated Balance Sheets as of June 30, 2025 (unaudited) and December 31, 2024 3 Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2025 and 2024 (unaudited) 4 Condensed Consolidated Statements of Comprehensive Loss for the three and six months ended June 30, 2025 and 2024 (unaudited) 5 Condensed Consolidated Statements of Stockholders' Equity for the three and six months ended June 30, 2025 and 2024 (unaudited) 6 Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2025 and 2024 (unaudited) 7 Notes to Condensed Consolidated Financial Statements (unaudited) 8

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 16

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk 23

Controls and Procedures

Item 4. Controls and Procedures 23

OTHER INFORMATION

PART II. OTHER INFORMATION

Legal Proceedings

Item 1. Legal Proceedings 24

Risk Factors

Item 1A. Risk Factors 24

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 61

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 61

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 61

Other Information

Item 5. Other Information 61

Exhibits

Item 6. Exhibits 62

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements aTyr Pharma, Inc. Condensed Consolida ted Balance Sheets (in thousands, except share and per share data) June 30, December 31, 2025 2024 (unaudited) Assets Current assets: Cash and cash equivalents $ 17,220 $ 11,055 Available-for-sale investments 63,126 61,070 Other receivables 498 1,736 Prepaid expenses 6,648 8,093 Total current assets 87,492 81,954 Restricted cash 2,878 2,951 Property and equipment, net 4,526 4,850 Operating lease, right-of-use assets 5,678 5,817 Financing lease, right-of-use assets 894 1,192 Other assets 66 66 Total assets $ 101,534 $ 96,830 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 3,881 $ 4,323 Accrued expenses 10,319 9,392 Current portion of operating lease liability 769 711 Current portion of financing lease liability 562 541 Total current liabilities 15,531 14,967 Long-term operating lease liability, net of current portion 10,745 11,144 Long-term financing lease liability, net of current portion 602 887 Commitments and contingencies (Note 4) Stockholders' equity: Preferred stock, $ 0.001 par value per share; 5,000,000 undesignated authorized shares as of June 30, 2025 (unaudited) and December 31, 2024, no shares issued or outstanding as of June 30, 2025 (unaudited) and December 31, 2024 — — Common stock, $ 0.001 par value per share; 170,000,000 authorized shares as of June 30, 2025 (unaudited) and December 31, 2024, issued and outstanding shares – 92,871,182 as of June 30, 2025 (unaudited) and 84,038,922 as of December 31, 2024 93 84 Additional paid-in capital 641,284 602,021 Accumulated other comprehensive loss ( 75 ) ( 40 ) Accumulated deficit ( 566,457 ) ( 532,046 ) Total aTyr Pharma, Inc. stockholders' equity 74,845 70,019 Noncontrolling interest in Pangu BioPharma Limited ( 189 )

View Full Filing

View this 10-Q filing on SEC EDGAR